Collegium expands board, appoints Nancy Lurker as new director

COLLEGIUM PHARMACEUTICAL, INC

Board expanded from 8 to 9 directors; Nancy Lurker appointed effective Feb 4, 2025.
Lurker, 67, former CEO of EyePoint Pharmaceuticals, currently vice chair of EyePoint board.
She will receive annual cash retainer of $50,000 (prorated) and equity award of $412,500 in RSUs vesting over 1 year.
Board determined Lurker is independent under Nasdaq rules; no related party transactions.
She also serves on boards of Alkermes (ALKS), Altasciences, and National Sanitation Foundation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nancy Lurker

Director

COLL · COLLEGIUM PHARMACEUTICAL, INC

Effective: 2025-02-04
Filed: February 5, 2025, 6:59 PM ET

approved the expansion of the Board from eight directors to nine directors and the appointment of Nancy Lurker to serve as a director of the Board, effective as of February 4, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Nancy Lurker was appointed as Director at COLLEGIUM PHARMACEUTICAL, INC.

Action: appointed
Role: Director

Exact text from the filing

approved the expansion of the Board from eight directors to nine directors and the appointment of Nancy Lurker to serve as a director of the Board, effective as of February 4, 2025

View on SEC.gov

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001104659-25-009384

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.